利索-全球专利检索

  1. 登录
  2. 注册
发明申请
US20120283288A1 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY 有权
1-（5-叔丁基-2-苯基-2H-吡唑-3-基）-3- [2-氟-4-（1-甲基-2-氧代-2,3-二氢-1H-咪唑并[ 4,5-B]吡啶-7-YLOXY） - 苯基] - 及其相关化合物及其在治疗中的用途

1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY
摘要：
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.
摘要（中）：

本发明一般涉及治疗化合物领域，更具体地涉及下列通式（I）的某些化合物（为了方便起见，本文统称为IP化合物），其尤其可用于治疗癌症 ，例如以突变RAS（突变RAS癌症）为特征的癌症（例如驱动的）。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗癌症中的用途，例如突变RAS癌症。

公开/授权文献
信息查询
Global Dossier Espacenet
0/0